All PlansCoverageMedium impact
Stem Cell Therapy for Peripheral Arterial Disease
Blue Cross & Blue Shield of Mississippi·Vascular Surgery, Cardiology, Wound Care +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy confirms that stem cell therapy for peripheral arterial disease remains investigational and not covered. The policy was reviewed with no changes - stem cell treatments including intramuscular autologous bone marrow cell therapy continue to be denied as investigational.
Action Required
Immediately: Billing team must verify denial protocols are in place for CPT codes 0263T, 0264T, and 0265T related to stem cell therapy for peripheral arterial disease. Ensure staff understand these services remain investigational and will be denied. Update denial reason templates to reference policy A.8.01.55.